Aim: The aim of this study was to investigate the effect of intracameral bevacizumab on the current hyphema.Material and Methods: The animals were assigned to the following 4 groups; Group 1: One 2.5 mg bevacizumab injection to theanterior chamber; Group 2: One 1.25 mg bevacizumab injection to the anterior chamber; Group 3: One 1cc balanced salt solutioninjection to the anterior chamber; and Group 4: Untreated hyphema group. Non-heparinized blood that obtained from the rabbit earwas used to fill the anterior chamber to create total hyphema. Intraocular pressures (IOP), hyphema resorption time, clot formation,peripheral synechia formation, and corneal staining were recorded.Results: IOP results were 26±1.2, 30±2.1, 24±2.9, and 22±0.0 mm Hg for groups 1, 2, 3, and 4, respectively, and were significantlyhigher in group 2 than in the other groups (p= 0.001). Resorption times of hyphema were 13±2.2, 13±3.2, 9±1.7, and 9±1.6 days forgroups 1, 2, 3, and 4, respectively, and were significantly longer for the groups receiving bevacizumab than for the others (p=0.018).The clot formation scores were 0.16±0.41, 0.14±0.38, 0.86±0.38, and 1.0±0.0 for groups 1, 2, 3, and 4, respectively, and weresignificantly lower for the groups receiving bevacizumab than in the other groups (p= 0.002). The peripheral synechia formationscores were 0.0±0.0, 0.0±0.0, 0.43±0.53, and 0.50±0.54 for groups 1, 2, 3, and 4, respectively, and were not significantly different (p=0.213). The corneal staining scores were 0.85±0.35, 0.86±0.38, 0.14±0.38, and 0.14±0.38 for groups 1, 2, 3, and 4, respectively, andwere significantly higher for the groups receiving bevacizumab (p= 0.035).Conclusion: Intracameral bevacizumab may increase complications that related current hyphema.